IPO Year: 2020
Exchange: NASDAQ
EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- PhenomeX (NASDAQ:CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately. Mr. Silvester most recently served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific and brings more than 25 years of experience in the life sciences tools industry as an executive and board member. "Peter's wealth of knowledge within the life sciences industry and experience in global business and commercial oper
Strategic Alternatives Process Continuing; Board Focused on Maximizing Stockholder Value EMERYVILLE, Calif., Aug. 14, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scien
EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists to leverage the fu
Company provides full year 2023 financial guidance EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the first quarter ended March 31, 2023. Following the completion of Berkeley Lights' acquisition of IsoPlexis on March 21, 2023, the newly combined company was rebranded as PhenomeX and is positioned to be the leading provider of life sciences solutions that have the greatest impact in advancing the era of the phenome as the next revolution in biology and medicine unfolds. Its brand reflects the Company's mission to empower scientists to leverage the full potential of each cell and drive the next
EMERYVILLE, Calif., April 27, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the first quarter 2023 after market on Thursday, May 11, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a
EMERYVILLE, Calif., Sept. 27, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the Beacon® optofluidic platform. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists
Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression.
New Beacon platform data to be presented by Genovac at Discovery on Target 2023 Poster and podium presentation featuring the Beacon platform to be presented at Annual Festival of Biologics Basel Conference & Exhibition EMERYVILLE, Calif., Sept. 20, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming cell biology conferences. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advan
Fully quantitative bulk and comprehensive single cell proteomics are now both available on the IsoSpark platform EMERYVILLE, Calif., Sept. 15, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced the launch of Meteor™ chips on the IsoSpark™ platform, providing a significant advancement in high throughput, quantitative, fully automated, multiplexed bulk proteomics. ™ CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insigh
EMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL) today announced that Bruker Corporation (NASDAQ:BRKR) has commenced, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for $1.00 per share. The tender offer is being made pursuant to the previously announced merger agreement between PhenomeX and Bruker entered into on August 17, 2023. Following the successful closing of the tender offer, Bird Mergersub Corporation will be merged into PhenomeX with PhenomeX becoming a wholly owned subsidiary of Bruker.
NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (NYSE:TMBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TMBR to LEO Pharma A/S for (i) an initial upfront consideration of $14 million and (ii) up to an additional $22 million in contingent value rights payable upon achievement of specific milestones for TMB-001. If you are a TIMBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Permian Resources Corporation (NYSE:PR)
Acquisition initiates Bruker's entry into functional single-cell biology research solutions Bruker Corporation (NASDAQ:BRKR) and PhenomeX Inc. (NASDAQ:CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction. The proposed acquisition values PhenomeX at a total equity value of approximately $108 million. PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages. This press release features multimedia. View the full release here: https://www.businesswir
Strategic Alternatives Process Continuing; Board Focused on Maximizing Stockholder Value EMERYVILLE, Calif., Aug. 14, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scien
EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists to leverage the fu
Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T Cell profiling, for precision immunotherapy translational research and accelerated development EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced the launch of the Beacon Quest™ optofluidic system, with Opto® T Cell Profiling workflows for immunotherapy translational research and a platform price under $1 million USD, less than half of the higher-throughput Beacon system, enabling broader accessibility to the cutting-
Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression. CELL) is empowering scientists to lever
Fully quantitative bulk and comprehensive single cell proteomics are now both available on the IsoSpark platform
On Monday, Cathie Wood-led Ark Invest made a significant move by continuing its buying spree of Archer Aviation Inc (NASDAQ:ACHR) shares. The investment firm purchased shares worth nearly $3.9 million, emphasizing its bullish stance on the flying car company. The Archer Aviation Trade: In total, Ark purchased nearly 604,000 shares of Archer Aviation. The transaction was valued at almost $3.9 million, based on the stock’s closing price of $6.39 on Monday. The purchases were made through ARK Innovation ETF (NYSE:ARKK), ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), and ARK Space Exploration & Innovation ETF (BATS:ARKX).Ark Invest’s recent acquisitions of Archer Aviation shares co
Upgrades For Beazer Homes USA Inc (NYSE:BZH), Sidoti & Co. upgraded the previous rating of Neutral to Buy. Beazer Homes USA earned $1.42 in the third quarter, compared to $1.76 in the year-ago quarter. The stock has a 52-week-high of $35.93 and a 52-week-low of $9.48. At the end of the last trading period, Beazer Homes USA closed at $28.23. Morgan Stanley upgraded the previous rating for Brown-Forman Corp (NYSE:BF) from Underweight to Overweight. For Suncor Energy Inc (NYSE:SU), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the second quarter, Suncor Energy had an EPS of $0.71, compared to year-ago quarter EPS of $2.12. The current stock performance of Sunc
TD Cowen analyst Steven Mah downgrades PhenomeX (NASDAQ:CELL) from Outperform to Market Perform and announces $1 price target.
Cathie Wood-led Ark Invest made significant trades on Tuesday, including a noteworthy move involving Zoom Video Communications (NASDAQ:ZM) and Nvidia Corporation (NASDAQ:NVDA). The Zoom trade took center stage, with Ark Invest purchasing $8.1 million worth of Zoom shares, based on Tuesday’s closing price of $65.83. Ark Invest purchased 122,831 shares of the company through ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). This move comes on the heels of recent developments that have kept Zoom in the spotlight. The company reported a strong earnings beat in the second quarter, accompanied by robust EPS guidance and the introduction of new AI features. Thes
Upgrades Stifel upgraded the previous rating for Fulcrum Therapeutics Inc (NASDAQ:FULC) from Hold to Buy. For the second quarter, Fulcrum Therapeutics had an EPS of $0.38, compared to year-ago quarter EPS of $0.83. The stock has a 52-week-high of $15.00 and a 52-week-low of $2.25. At the end of the last trading period, Fulcrum Therapeutics closed at $3.92. For Restaurant Brands International Inc (NYSE:QSR), Northcoast Research upgraded the previous rating of Neutral to Buy. Restaurant Brands Intl earned $0.85 in the second quarter, compared to $0.82 in the year-ago quarter. The stock has a 52-week-high of $78.30 and a 52-week-low of $51.28. At the end of the last trading period, Restauran
Berenberg analyst Gaurav Goparaju downgrades PhenomeX (NASDAQ:CELL) from Buy to Hold and lowers the price target from $8 to $1.
On Monday, August 21, 2023, Cathie Wood-led Ark Invest made significant moves in the market, with a notable decision to sell $9.2 million worth of shares of Shopify Inc (NYSE:SHOP). This comes in the wake of Shopify's recent volatility following its Q2 results. The Shopify Trade: Ark sold 170335 shares of Shopify through ARK Next Generation Internet ETF (NYSE:ARKW) and Ark Fintech Innovation ETF (NYSE:ARKF). The transaction was valued at $9.2 million, based on Shopify stock’s closing price of $53.93 on Monday. Ark Invest’s decision to sell Shopify shares across various ETFs is a continuation of its recent trading behavior. Earlier this week, Ark Invest also made a notable decision
Upgrades For Docebo Inc (NASDAQ:DCBO), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. For the second quarter, Docebo had an EPS of $0.14, compared to year-ago quarter EPS of $0.06. The current stock performance of Docebo shows a 52-week-high of $41.48 and a 52-week-low of $23.40. Moreover, at the end of the last trading period, the closing price was at $40.66. For American Woodmark Corp (NASDAQ:AMWD), Zelman & Assoc upgraded the previous rating of Hold to Buy. In the fourth quarter, American Woodmark showed an EPS of $2.21, compared to $1.38 from the year-ago quarter. At the moment, the stock has a 52-week-high of $78.22 and a 52-week-low of $41.20. American Wo